Cargando…

Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome

Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy that may lead to organ failure. Dysregulation of the complement system can cause aHUS, and various disease‐related variants in the complement regulatory protein CD46 are described. We here report a pediatric patient with aHUS...

Descripción completa

Detalles Bibliográficos
Autores principales: Schack, Vivien R., Herlin, Morten K., Pedersen, Henrik, Jensen, J. Magnus Bernth, Færch, Mia, Bundgaard, Bettina, Jensen, Rasmus K., Jensen, Uffe B., Christensen, Rikke, Andersen, Gregers R., Thiel, Steffen, Höllsberg, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804674/
https://www.ncbi.nlm.nih.gov/pubmed/35987516
http://dx.doi.org/10.1002/eji.202249838
_version_ 1784862163786006528
author Schack, Vivien R.
Herlin, Morten K.
Pedersen, Henrik
Jensen, J. Magnus Bernth
Færch, Mia
Bundgaard, Bettina
Jensen, Rasmus K.
Jensen, Uffe B.
Christensen, Rikke
Andersen, Gregers R.
Thiel, Steffen
Höllsberg, Per
author_facet Schack, Vivien R.
Herlin, Morten K.
Pedersen, Henrik
Jensen, J. Magnus Bernth
Færch, Mia
Bundgaard, Bettina
Jensen, Rasmus K.
Jensen, Uffe B.
Christensen, Rikke
Andersen, Gregers R.
Thiel, Steffen
Höllsberg, Per
author_sort Schack, Vivien R.
collection PubMed
description Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy that may lead to organ failure. Dysregulation of the complement system can cause aHUS, and various disease‐related variants in the complement regulatory protein CD46 are described. We here report a pediatric patient with aHUS carrying a hitherto unreported homozygous variant in CD46 (NM_172359.3:c.602C>T p.(Ser201Leu)). In our functional analyses, this variant caused complement dysregulation through three separate mechanisms. First, CD46 surface expression on the patient's blood cells was significantly reduced. Second, stably expressing CD46(Ser201Leu) cells bound markedly less to patterns of C3b than CD46 WT cells. Third, the patient predominantly expressed the rare isoforms of CD46 (C dominated) instead of the more common isoforms (BC dominated). Using BC1 and C1 expressing cell lines, we found that the C1 isoform bound markedly less C3b than the BC1 isoform. These results highlight the coexistence of multiple mechanisms that may act synergistically to disrupt CD46 function during aHUS development.
format Online
Article
Text
id pubmed-9804674
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98046742023-01-06 Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome Schack, Vivien R. Herlin, Morten K. Pedersen, Henrik Jensen, J. Magnus Bernth Færch, Mia Bundgaard, Bettina Jensen, Rasmus K. Jensen, Uffe B. Christensen, Rikke Andersen, Gregers R. Thiel, Steffen Höllsberg, Per Eur J Immunol Immunodeficiencies and autoimmunity Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy that may lead to organ failure. Dysregulation of the complement system can cause aHUS, and various disease‐related variants in the complement regulatory protein CD46 are described. We here report a pediatric patient with aHUS carrying a hitherto unreported homozygous variant in CD46 (NM_172359.3:c.602C>T p.(Ser201Leu)). In our functional analyses, this variant caused complement dysregulation through three separate mechanisms. First, CD46 surface expression on the patient's blood cells was significantly reduced. Second, stably expressing CD46(Ser201Leu) cells bound markedly less to patterns of C3b than CD46 WT cells. Third, the patient predominantly expressed the rare isoforms of CD46 (C dominated) instead of the more common isoforms (BC dominated). Using BC1 and C1 expressing cell lines, we found that the C1 isoform bound markedly less C3b than the BC1 isoform. These results highlight the coexistence of multiple mechanisms that may act synergistically to disrupt CD46 function during aHUS development. John Wiley and Sons Inc. 2022-08-31 2022-10 /pmc/articles/PMC9804674/ /pubmed/35987516 http://dx.doi.org/10.1002/eji.202249838 Text en © 2022 The Authors. European Journal of Immunology published by Wiley‐VCH GmbH. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Immunodeficiencies and autoimmunity
Schack, Vivien R.
Herlin, Morten K.
Pedersen, Henrik
Jensen, J. Magnus Bernth
Færch, Mia
Bundgaard, Bettina
Jensen, Rasmus K.
Jensen, Uffe B.
Christensen, Rikke
Andersen, Gregers R.
Thiel, Steffen
Höllsberg, Per
Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome
title Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome
title_full Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome
title_fullStr Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome
title_full_unstemmed Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome
title_short Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome
title_sort novel homozygous cd46 variant with c‐isoform expression affects c3b inactivation in atypical hemolytic uremic syndrome
topic Immunodeficiencies and autoimmunity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804674/
https://www.ncbi.nlm.nih.gov/pubmed/35987516
http://dx.doi.org/10.1002/eji.202249838
work_keys_str_mv AT schackvivienr novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome
AT herlinmortenk novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome
AT pedersenhenrik novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome
AT jensenjmagnusbernth novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome
AT færchmia novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome
AT bundgaardbettina novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome
AT jensenrasmusk novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome
AT jensenuffeb novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome
AT christensenrikke novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome
AT andersengregersr novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome
AT thielsteffen novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome
AT hollsbergper novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome